摘要
目的比较含雷贝拉唑与含兰索拉唑三联疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡的临床疗效。方法纳入本院门诊收治的Hp阳性消化性溃疡患者86例,随机分为2组。治疗组44例,给予雷贝拉唑+阿莫西林+克拉霉素,对照组42例,给予兰索拉唑+阿莫西林+克拉霉素。疗程结束停药4周后复查胃镜、快速尿素酶试验及14C呼气试验,观察溃疡愈合及Hp根除情况。结果治疗组溃疡愈合的治愈率、Hp根除率均高于对照组,而Hp感染复发率显著降低,且不良反应发生率低。结论雷贝拉唑、阿莫西林、克拉霉素的三联疗法治疗Hp阳性的消化性溃疡患者,可显著提高溃疡愈合的治愈率、Hp根除率,降低Hp感染的复发率,且安全性好,是较为理想的治疗方案,值得大力推广。
Objective To compare the clinical efficacy of rabeprazole and lanprazole triple therapy for Helicobacter pylori （Hp） - positive peptic ulcer. Methods Eighty - six Hp - positive peptic ulcer patients who were admitted into our hospital were randomly divided into two groups. The treatment group （n =44） received rabeprazole ＋ amoxicillin ＋ clarithromycin, and the con- trol group （n -42） received lan^prazole ＋ amoxicillin ＋ clarithromycin. Endoscopy, rapid urease test and ~ breath test were conducted 4 weeks after medication was stopped. Ulcer healing and Hp eradication were observed. Results The cure rate, ulcer healing, and Hp eradication rate were higher in the treatment group than in the control group. The rate of Hp infection recurrence was significantly reduced, and there was low incidence of adverse reactions. Conclusion For the treat- ment of Hp - positive patients with peptic ulcer, the triple therapy of rabeprazole, amoxicillin, and clarithromycin can significantly improve ~he cure rate of ulcer healing and Hp eradication, reduce the recurrence rate of Hp infection with more safety. It is an ideal treatment scheme and is worth promoting.
出处
《实用临床医药杂志》
CAS
2012年第17期92-93,共2页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220111)
